MUVON Therapeutics
MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich, developing a therapeutic platform for skeletal muscle tissue regeneration based on autologous cells. Their mission is to provide safe, effective, and affordable treatments for debilitating diseases, initially focusing on stress urinary incontinence in women. They aim to develop personalized regenerative treatments to extend human health-span and address high unmet medical needs caused by muscle damage or degradation.
Industries
Nr. of Employees
small (1-50)
MUVON Therapeutics
c/o ETH Zürich, Weinbergstrasse 35, WEH G-Stock, 8092 Zürich, Switzerland
Products
Autologous Muscle Tissue Regeneration
A therapy platform for skeletal muscle regeneration using the patient's own muscle precursor cells, targeting diseases like stress urinary incontinence.
Phase II Clinical Trial for Stress Urinary Incontinence
An ongoing clinical trial investigating the efficacy of autologous muscle tissue regeneration therapy in women with stress urinary incontinence.
Good Manufacturing Practice (GMP) Compliance
Ensures the production process of therapies meets the required quality standards.
Good Clinical Practice (GCP) Compliance
Ensures clinical trials are conducted according to ethical and scientific quality standards.
Autologous Muscle Tissue Regeneration
A therapy platform for skeletal muscle regeneration using the patient's own muscle precursor cells, targeting diseases like stress urinary incontinence.
Phase II Clinical Trial for Stress Urinary Incontinence
An ongoing clinical trial investigating the efficacy of autologous muscle tissue regeneration therapy in women with stress urinary incontinence.
Good Manufacturing Practice (GMP) Compliance
Ensures the production process of therapies meets the required quality standards.
Good Clinical Practice (GCP) Compliance
Ensures clinical trials are conducted according to ethical and scientific quality standards.
News & Updates
UVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.
MUVON clears phase 2 interim milestone and announces participation in the 2025 J.P. Morgan Healthcare Conference.
MUVON CEO, Deana Mohr-Haralampieva, was recently featured in an exclusive interview with PharmaBoardroom.
MUVON ranked as a top 3 Biotech and overall 18th in 2024s TOP 100 Swiss Startups ranking.
Our latest paper has been published in Nature Reviews Bioengineering: Down to Business, discussing our approach for treating stress urinary incontinence.
MUVON was featured by Nature as a leader in innovative treatments for stress urinary incontinence.
UVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the last patient in its phase 2 clinical study.
MUVON clears phase 2 interim milestone and announces participation in the 2025 J.P. Morgan Healthcare Conference.
MUVON CEO, Deana Mohr-Haralampieva, was recently featured in an exclusive interview with PharmaBoardroom.
MUVON ranked as a top 3 Biotech and overall 18th in 2024s TOP 100 Swiss Startups ranking.
Our latest paper has been published in Nature Reviews Bioengineering: Down to Business, discussing our approach for treating stress urinary incontinence.
MUVON was featured by Nature as a leader in innovative treatments for stress urinary incontinence.